Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 227Other hematologic neoplasm 75Plasma cell 9Myeloid 9Sarcoma 8Dermatologic 7CNS 4Breast 2Tumor-Agnostic 1Thoracic 1Other neoplasm 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Precancerous Conditions 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Oxycodone 2tremelimumab 1penpulimab 1peginterferon alfa-2b 1Zoledronic Acid 1Zidovudine 1Whole-Body Irradiation 1Valproic Acid 1Tetradecanoylphorbol Acetate 1Surveys and Questionnaires 1Sodium Chloride 1Selenium 1Rosuvastatin Calcium 1Rituximab 1Ribavirin 1Radiosurgery 1Proflavine 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Observation 1Moxifloxacin 1Morphine 1Microarray Analysis 1Methotrexate 1Methadone 1Laser Therapy 1Interferon alpha-2 1Infliximab 1Gene Expression Profiling 1Gadolinium DTPA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rituximab × Other neoplasm × Clear all
NCT00588822 2014-05-06

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

Mayo Clinic

Phase 2 Terminated
21 enrolled 11 charts
Other neoplasm

Monoclonal Gammopathy of Undetermined Significance, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡